YMAB Total Stockholder Equity from 2010 to 2024
| YMAB Stock | USD 11.88 1.11 10.31% |
Total Stockholder Equity | First Reported 2016-12-31 | Previous Quarter 95.3 M | Current Value 92.4 M | Quarterly Volatility 52 M |
Check Y MAbs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Y MAbs' main balance sheet or income statement drivers, such as Interest Expense of 821.4 K, Selling General Administrative of 33.2 M or Total Revenue of 89.1 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 2.8. YMAB financial statements analysis is a perfect complement when working with Y MAbs Valuation or Volatility modules.
YMAB | Total Stockholder Equity |
Latest Y MAbs' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Y mAbs Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Y MAbs' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Y MAbs' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
YMAB Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 75,333,551 | |
| Geometric Mean | 42,073,406 | |
| Coefficient Of Variation | 89.79 | |
| Mean Deviation | 59,054,381 | |
| Median | 82,152,000 | |
| Standard Deviation | 67,644,872 | |
| Sample Variance | 4575.8T | |
| Range | 186.8M | |
| R-Value | 0.78 | |
| Mean Square Error | 1962.3T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | 11,733,914 | |
| Total Sum of Squares | 64061.6T |
YMAB Total Stockholder Equity History
About Y MAbs Financial Statements
Y MAbs stakeholders use historical fundamental indicators, such as Y MAbs' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Y MAbs investors may analyze each financial statement separately, they are all interrelated. For example, changes in Y MAbs' assets and liabilities are reflected in the revenues and expenses on Y MAbs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Y mAbs Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 101 M | 127.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out the analysis of Y MAbs Correlation against competitors. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.